interferon beta-1b: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
interferon beta-1b: clinical details
Prescribing considerations
- Initiate under the supervision of a clinician experienced in MS treatment.
- Assess current and previous depression, suicidal ideation, liver disease, seizures, renal impairment, cardiac disease and monoclonal gammopathy.
- Review disease activity and tolerability when deciding whether treatment remains appropriate.
- Record product name and batch number for biological-medicine traceability.
Contraindications and cautions
- Hypersensitivity to natural or recombinant interferon beta, human albumin or an excipient
- Current severe depression and/or suicidal ideation
- Decompensated liver disease
Monitoring
- Full blood count with differential and platelets, blood chemistry and liver function before treatment and regularly thereafter
- Thyroid function in people with previous thyroid dysfunction or when clinically indicated
- Mood and suicidal ideation; injection technique and injection-site integrity
- Renal function when clinically indicated and assessment for symptoms suggesting nephropathy or thrombotic microangiopathy
- Clinical status in people with seizures or cardiac disease
Clinical pharmacology
A recombinant cytokine produced using genetically modified Escherichia coli. It has immunoregulatory and antiviral activity mediated through cell-surface interferon receptors, although its complete therapeutic mechanism in MS is unresolved.
Formulation and product differences
- The product is a powder with a separate sodium chloride solvent and must be reconstituted before subcutaneous injection.
- The powder contains human albumin and mannitol; the prepared product is essentially sodium-free.
- It may be administered using a suitable autoinjector.
- It must not be mixed with medicines other than the supplied solvent.
interferon beta-1b interactions
Formal interaction studies are limited. Tell the prescriber about all medicines, including non-prescription products.
Other immunomodulators
Combined use is not recommended because clinical experience is lacking, apart from corticosteroids or ACTH used for relapses.
Narrow-therapeutic-index medicines cleared by hepatic cytochrome P450, including some antiepileptics such as phenytoin
Interferons may reduce hepatic enzyme activity, so additional clinical or laboratory monitoring may be needed.
Medicines affecting blood-cell production
Combined effects may increase blood-count abnormalities and require closer monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.